Alza Delivery Technologies Reduce Drug Enhancement Costs To $80 Mil.

30 Sep 2002
News

The Pink Sheet pinkeditor@informa.com

Executive Summary

Alza drug delivery technologies reduce the cost of developing an enhanced version of an already-marketed drug to $70 mil.-$80 mil., Alza Chairman Sam Saks, MD, said during Johnson & Johnson's business review Sept. 23

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS040527

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS040527

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Alza Delivery Technologies Reduce Drug Enhancement Costs To $80 Mil.

News

Executive Summary

Related Content

Lilly cashes out on dapoxetine

Lilly cashes out on dapoxetine

Tufts R&D Cost Estimate Puts Cash Outlay At $403 Mil. Per NCE

J&J's Revamped R&D Will Release First Drug In 2004, Diabetic Likely Choice

J&J Risperdal, Topamax Are Candidates For Alza Drug Delivery Systems

J&J Risperdal, Topamax Are Candidates For Alza Drug Delivery Systems

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert